“I still have a lot of living left to do” - Sue’s story 21 Nov 2022 When Sue Vincent learned in 2010 that her ovarian cancer had spread to three different parts of her body and was inoperable, she resigned herself to having only months to live. But then she was offered a place on a clinical trial for a pioneering drug called olaparib, the discovery and development of which was underpinned by our research. 12 years on, Sue is still taking olaparib, and explains how the work of our scientists has given her a quality of life she could only have dreamed about. Find out more Show/Hide
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 04 Jun 2021 The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough. Find out more Show/Hide
Prostate Cancer Awareness Month 2020: Immunotherapy, state-of-the-art radiotherapy, olaparib and PSA screening 24 Mar 2020 March is Prostate Cancer Awareness Month. Web Editor Dave Morgan reviews four recent news stories covering different types of prostate cancer research taking place at The Institute of Cancer Research. Find out more Show/Hide
“Here you really can make a difference” – Professor Chris Lord reflects on the biggest developments in his career so far 18 Oct 2018